Summary
This literature review searched EBSCOhost Academic Search Premier, Proquest, Google Scholar, and the Cochrane Library in June 2022 for published treatments for chronic inflammatory response syndrome (CIRS), ME/CFS, and sick building syndrome. No patients were enrolled by the review; no comparison group, randomization, or follow-up duration was reported. The review reports 13 articles comprising 14 studies on CIRS treatment and also reviews CFS treatment studies. Named CIRS study sizes included 8, 13, 28, 14, 21, 156/111, 20, 35/4, 100, and 68/23. The review states the only treatment with documented clinical efficacy was the Shoemaker Protocol, described in 11 of the 13 articles; table entries list cholestyramine and vasoactive intestinal peptide as successful, while Rea’s antigen intradermal treatments had lack of objective data. CFS studies listed sizes including 49, 1518, 1030, 2036, 62, 409, 101, 171, 33, 32/18, 23, and 218; findings included some benefit for aripiprazole in 101 patients, high frequency of response for low-dose naltrexone in 218, and CBT/GET reported beneficial in six studies but noncurative. Reported side effects include constipation from cholestyramine, hyponatremia from desmopressin, and light-headedness from vasoactive intestinal peptides; medication intolerance was a barrier.